Chronic heart failure Circulatory System
Conditions
Interventions
This study enrolls patients who have already been administered the study drug in line with the indication described on the label based on the doctor’s decision. After that, the investigator collects i
Sponsors
Servier (Tianjin) Pharmaceutical Co., Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female, outpatients or inpatients, over 18 (inclusive) years old 2. Sinus rhythm 3. Resting heart rate =75 bpm as measured by 12-lead ECG prior to enrollment 4. Chronic heart failure patients with systolic dysfunction (the left ventricular ejection fraction (LVEF) was = 40 % in the last 3 months) 5. Patients whose cardiac function classification according to the New York Heart Association (NYHA) standard are class 2-4 6. Patients who have received standard treatment (including ß-blockers) for heart failure, or are intolerable or contraindicated to ß-blockers 7. Patients who meet the indication of Corlentor® and are starting to receive Corlentor® treatment 8. Patients who have signed the informed consent forms
Exclusion criteria
Exclusion criteria: 1. Patients who have received the treatment with Corlentor® within 2 weeks 2. Recent (<1 month) occurrence of acute myocardial infarction 3. Acute heart failure and cardiogenic shock 4. Sick sinus syndrome or sino-atrial block 5. Third-degree atrioventricular block 6. Severe hypotension (<90/50 mmHg) 7. Severe liver dysfunction (Child-Pugh score =10) 8. End-stage renal failure (Plasma creatinine clearance <15 ml/min) 9. Pregnancy, lactation and women of child-bearing potential not using appropriate contraceptive measures 10. Patients unable to visit as scheduled
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart rate change after Corlentor® administration, measured using office daytime resting heart rate (heart rate and rhythm from the 12-lead ECG will also be considered for double-confirm if available) at the 1-month and 6-month visit | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at the 1-month and 6-month visit: 1. Heart failure symptoms, measured based on the inquisition and physical examination carried out by cardiologists 2. Left ventricular function, measured by echocardiogram 3. Heart failure biomarker (BNP and/or NT-proBNP), assessed with a routine laboratory test 4. Quality of life, assessed by KCCQ questionnaire 5. Safety and tolerability of Corlentor®, measured through monitoring adverse drug reactions and changes of laboratory indicators after administration of the drug | — |
Countries
China
Outcome results
None listed